COX-2 expression has been reported in a significant proportion of preinvasive and invasive breast cancers [10,13], and different frequencies of COX-2 over-expression have been observed in subgroups of breast cancer patients by hormone receptor status (estrogen receptor [ER] and progesterone receptor [PR]). This evidence concerns the gene ESR1 and breast carcinoma.